Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
44%(4 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_1
10
91%
Ph phase_2
1
9%

Phase Distribution

10

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
10(90.9%)
Phase 2Efficacy & side effects
1(9.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(2)

Detailed Status

Completed9
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
81.8%
Most Advanced
Phase 2

Trials by Phase

Phase 110 (90.9%)
Phase 21 (9.1%)

Trials by Status

completed982%
terminated218%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_1

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

NCT02332798
terminatedphase_2

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

NCT02855411
completedphase_1

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

NCT02341482
completedphase_1

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

NCT02228395
completedphase_1

First-in-Human Study of PF-04958242 in Healthy Volunteers

NCT01159483
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02332798Phase 1

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

Completed
NCT02855411Phase 2

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Terminated
NCT02341482Phase 1

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

Completed
NCT02228395Phase 1

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Completed
NCT01159483Phase 1

First-in-Human Study of PF-04958242 in Healthy Volunteers

Completed
NCT01238679Phase 1

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

Terminated
NCT01365338Phase 1

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

Completed
NCT01518920Phase 1

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Completed
NCT01749098Phase 1

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

Completed
NCT01518894Phase 1

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Completed
NCT01511510Phase 1

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11